PTHS (PTHS) reported SG&A of $21.1M in Q1 2026.

How has PTHS's SG&A changed year-over-year?

PTHS's SG&A increased by 1186.8% year-over-year, from $1.64M to $21.1M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

PTHS PTHS SG&A

SG&A at other companies

Journey Medical CorporationDERM

$10.11M-4.4%

Opko HealthOPK

$48.61M-17.7%

Zevra Therapeutics, Inc.ZVRA

$20.78M+6.3%

Theravance BiopharmaTBPH

$17.72M-3.5%

HRO

HarrowHROW

$43.23M+6.7%

Arcutis Biotherapeutics, Inc.ARQT

$74.08M+15.7%

Other financials

Income statement

See full

Revenue$10.9M—

Gross profit$9.2M—

Operating income-$13.1M-614%

Net income-$10.2M-420%

EPS (diluted)-$3.09+3.7%

Balance sheet

See full

Cash & equivalents$32.0M+24,250%

Total debt$29.6M—

Total equity$35.1M+937%

Total assets$145.4M+15,855%

Cash flow

See full

Operating cash flow-$13.1M-1,977%

CapEx$194.0K—

Free cash flow-$13.3M-2,008%

Valuation

See full

Market cap$98.22M+92.4%

Enterprise value$95.89M—

P/S3.6×—

Profitability

See full

Gross margin79.6%—

Operating margin-157.7%—

Net margin-186.2%—

FCF margin-60.8%—

Returns & leverage

See full

Return on equity-333.8%—

Debt / equity0.8×—

Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTHS's SG&A?: PTHS (PTHS) reported SG&A of $21.1M in Q1 2026.
How has PTHS's SG&A changed year-over-year?: PTHS's SG&A increased by 1186.8% year-over-year, from $1.64M to $21.1M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.